Analysis of the molecular expression profile of non small cell lung carcinoma associated to chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) is an independent risk factor to develop lung cancer but there are no different functional clusters of biomarkers between patients with non-small cell lung cancer (NSCLC) with or without COPD. To analyse protein expression, in order to find out whether samples of resected NSCLC from patients with COPD present a different molecular expression. Observational, cohort, concurrent study with sampling since treatment of disease in patients with NSCLC in initial stages (pIA-pIIB) treated surgically in our hospital between October 1993 and September 1997. The study consisted of the elaboration of tissue arrays with samples from resected tumor, using immunohistochemistry as a study method. Univariate analysis and logistic regression analysis were performed in order to determine molecular markers that showed a differential expression in NSCLC of the patients with COPD. We studied thirty-two proteins in 146 patients. 30% of the patients had COPD. Univariate analysis in patients with COPD showed one molecular marker to be overexpressed and five molecular markers to be underexpressed. Multivariate analysis in patients with COPD identified membranous beta-Catenin as a differential biomarker, which displayed an underexpression, with an Odds Ratio (95% Confidence Interval) of 0.26 (0.07-1.01). A significant lowest expression of membranous beta-catenin was detected in NSCLC of the patients with COPD.
Garcia-Lujan
Ricardo
R
Department of Pneumology, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, Madrid, Spain. rglujan@hotmail.com
Conde-Gallego
Esther
E
Lopez-Ríos
Fernando
F
Martin de Nicolas
Jose Luis
JL
Sanchez-Céspedes
Montserrat
M
García-Quero
Cristina
C
Echave-Sustaeta
Jose Maria
JM
Lopez-Encuentra
Angel
A
D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000096:biosynthesis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000378:metabolism*; D053148:Caspase 3 / Q000032:analysis / Q000096:biosynthesis; D018797:Cell Cycle Proteins / Q000032:analysis / Q000096:biosynthesis; D051546:Cyclooxygenase 2 / Q000032:analysis / Q000096:biosynthesis; D015536:Down-Regulation; D053222:Fas Ligand Protein / Q000032:analysis / Q000096:biosynthesis; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications / Q000378:metabolism*; D008297:Male; D008565:Membrane Proteins / Q000032:analysis / Q000096:biosynthesis; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis / Q000096:biosynthesis; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000378:metabolism*; D012307:Risk Factors; D046888:Tissue Array Analysis; D015854:Up-Regulation; D051176:beta Catenin / Q000032:analysis / Q000096:biosynthesis
D014408:Biomarkers, Tumor; C103706:CDC6 protein, human; C495270:CTNNB1 protein, human; D018797:Cell Cycle Proteins; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008565:Membrane Proteins; D009687:Nuclear Proteins; D051176:beta Catenin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; C505407:CASP3 protein, human; D053148:Caspase 3